Yep he mentions batch consistency, MOA and biomarkers as key issues they are resolving and that the FDA interactions are more cohesive and positive, working towards a common goal. That sounds potentially very good. The only one throwing rocks last July was Incycte/Novartis and Novartis are in the tent now.... only a matter of time IMO. kaboom
Yep he mentions batch consistency, MOA and biomarkers as key...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |